Travere Therapeutics, Inc. (TVTX) Financials
TVTX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 788.9 million | 588.1 million |
2023-09-30 | 832.9 million | 553.1 million |
2023-06-30 | 736.4 million | 619.9 million |
2023-03-31 | 808.2 million | 619.1 million |
TVTX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -76.0 million | 8.1 million |
2023-09-30 | -64.7 million | 10.7 million |
2023-06-30 | -72.5 million | 11.6 million |
2023-03-31 | -109.1 million | 13.8 million |
TVTX Net Income
No data available :(
TVTX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 566.9 million | - | 27.5 million |
2023-09-30 | 634.6 million | - | 28.6 million |
2023-06-30 | 491.3 million | 376.4 million | 29.8 million |
2023-03-31 | 561.5 million | 376.0 million | 30.9 million |
TVTX Shares Outstanding
TVTX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 5.5 million | 58.7 million | 63.6 million | -10.9 million |
2023-09-30 | 5.6 million | 60.6 million | 67.8 million | - |
2023-06-30 | 3.2 million | 69.4 million | 75.9 million | - |
2023-03-31 | 28.0 million | 59.9 million | 79.0 million | - |
TVTX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 45.1 million | 16.4 million |
2023-09-30 | 37.1 million | 1.3 million |
2023-06-30 | 59.7 million | 2.0 million |
2023-03-31 | 57.0 million | 5.1 million |
TVTX
Price: $6.26
52 week price:
Earnings Per Share: -5.07 USD
P/E Ratio: -1.88
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 1.1 million
Market Capitalization: 476.4 million